Shopping Cart

Your shopping cart is currently empty

13-Methyltetradecanoic acid (Synonyms: LeDSF3, 13-MTD, 13-Methylmyristic acid)

Name: 13-Methyltetradecanoic acid
Brand: TargetMol
SKU: T27807
Price: 35 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T27807 Copy Product Info

Purity: 99.98%

🥰Excellent

13-Methyltetradecanoic acid (13-MTD) is a saturated branched-chain fatty acid with potent anticancer effects. It induces apoptosis in various human cancer cells, such as bladder cancer and T-cell lymphoma. The pro-apoptotic mechanism is primarily mediated through the mitochondrial pathway, involving the down-regulation of Bcl-2 and up-regulation of Bax, which leads to mitochondrial dysfunction, cytochrome c release, and subsequent proteolytic activation of caspases. Additionally, 13-MTD down-regulates AKT phosphorylation and activates the phosphorylation of p38 and c-Jun N-terminal kinase (JNK).

13-Methyltetradecanoic acid

Copy Product Info

🥰Excellent

Catalog No. T27807

Synonyms LeDSF3, 13-MTD, 13-Methylmyristic acid

Cas No. 2485-71-4

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$35	-	In Stock
5 mg	$81	-	In Stock
10 mg	$139	-	In Stock
25 mg	$247	-	In Stock
50 mg	$413	-	In Stock
100 mg	$689	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.98%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	13-Methyltetradecanoic acid (13-MTD) is a saturated branched-chain fatty acid with potent anticancer effects. It induces apoptosis in various human cancer cells, such as bladder cancer and T-cell lymphoma. The pro-apoptotic mechanism is primarily mediated through the mitochondrial pathway, involving the down-regulation of Bcl-2 and up-regulation of Bax, which leads to mitochondrial dysfunction, cytochrome c release, and subsequent proteolytic activation of caspases. Additionally, 13-MTD down-regulates AKT phosphorylation and activates the phosphorylation of p38 and c-Jun N-terminal kinase (JNK).
In vitro	13-Methyltetradecanoic acid (0–140 μg/mL) dose- and time-dependently inhibits bladder cancer cell proliferation. At 70 μg/mL, it increases the sub-G1 population from 9.25% to 85.3%. Mechanistically, it disrupts the Bcl-2/Bax balance, activates caspases, suppresses AKT, and activates JNK/p38 signaling to promote apoptosis [1].
In vivo	In vivo, 13-Methyltetradecanoic acid (70 mg/kg/day, oral gavage, 30 days) significantly suppresses tumor growth in a Jurkat lymphoma xenograft model using BALB/C nude mice. Research confirms its effective oral antitumor potency, with a mechanism consistent with the in vitro observations of p-AKT inhibition and Caspase-3 activation [2].
Synonyms	LeDSF3, 13-MTD, 13-Methylmyristic acid

Chemical Properties

Molecular Weight	242.4
Formula	C₁₅H₃₀O₂
Cas No.	2485-71-4
Smiles	O=C(O)CCCCCCCCCCCC(C)C
Relative Density.	0.894 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 80 mg/mL (330.03 mM)

Solution Preparation Table

Ethanol

	1mg	5mg	10mg	50mg
1 mM	4.1254 mL	20.6271 mL	41.2541 mL	206.2706 mL
5 mM	0.8251 mL	4.1254 mL	8.2508 mL	41.2541 mL
10 mM	0.4125 mL	2.0627 mL	4.1254 mL	20.6271 mL
20 mM	0.2063 mL	1.0314 mL	2.0627 mL	10.3135 mL
50 mM	0.0825 mL	0.4125 mL	0.8251 mL	4.1254 mL
100 mM	0.0413 mL	0.2063 mL	0.4125 mL	2.0627 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc